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Chimeric antigen receptor T cell (CAR-T cell) is a breakthrough 
technological advancement combining cellular therapy, targeted 
therapy, and gene therapy. Its principle is the ex vivo modification 
of receptors of autologous or allogeneic T-lymphocytes, which after 
reinfusion to patients can treat malignancies. So far, it is the best model 
facing concept of individualized precision medicine. After amazing 
progress with intercontinental clinical trials, followed by licensing by 
the American Food and Drug Administration Agency and European 
Medicines Agency, adoptive cellular immunotherapy with CAR-T cells 
has already changed the treatment landscape in relapsed/refractory 
B-cell malignancies.
On November 28, 2019, for the first time in Poland, CAR-T cells were 
administered to patients by a team led by Prof. Lidia Gil in Department 
of Hematology and Bone Marrow Transplantation in Poznań [1]. It was 
exactly 35 years after the first successful allogeneic hematopoietic 
cell transplantation in Poland, which was done by Prof. Wiesław 
Jędrzejczak in Warsaw on November 28, 1984.
Two other transplant centers are already prepared and accredited for 
this therapy. Several others will be ready in the forthcoming future. 
National health authorities will have to follow this unusual therapeutic 
opportunity and adjust reimbursement system for Polish patients.
CAR-T cell is probably the most important development in anticancer 
therapy [2, 3, 4]. So far, it is feasible only for B-cell lineage hematological 
malignancies, but the door has been opened for further research and 
progress. CAR-T cell era has also started in Poland.
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